軽度から中等度のクローン病患者におけるファスティング模倣食:ランダム化比較試験
C Kulkarni1, T Fardeen1, J Gubatan1
1Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Nature medicine
|January 13, 2026
まとめ
ファスティング模倣食(FMD)の短いサイクルは、クローン病(CD)患者の臨床的奏効と寛解を著しく改善した。FMDは標準食よりも優れた結果を示し、炎症マーカーを減少させた。
科学分野:
- 消化器病学および肝臓病学
- 免疫学
- 栄養科学
背景:
- ファスティング模倣食(FMD)の短いサイクルは、健常者の炎症を軽減し、代謝健康を改善することが知られている。
- FMDの有効性は、慢性炎症性疾患であるクローン病(CD)患者では以前に研究されていなかった。
研究 の 目的:
- 軽度から中等度のクローン病(CD)成人患者におけるファスティング模倣食(FMD)の臨床転帰への影響を評価すること。
- CD患者におけるFMDの炎症マーカーおよび代謝健康への影響を評価すること。
主な方法:
- 軽度から中等度のCDと診断された成人患者を対象に、オープンラベルのランダム化比較試験を実施した。
- 参加者は2つのグループにランダム化された。1つのグループは3ヶ月間毎月5日間のFMDに従い、対照グループはベースラインの食事を維持した。
- 主要評価項目は、CD活動指数(CDAI)の低下またはCDAIスコアが150以下と定義された臨床的奏効であった。
主要な成果:
- FMD群の患者の有意に高い割合が対照群(43.8%)と比較して臨床的奏効(69.2%)を達成した(P=0.03)。
- FMD群はまた、臨床的寛解率(64.6%)が対照群(37.5%)よりも有意に高かった(P=0.02)。
- FMD介入は、対照群(8.0%)と比較して、主要な炎症マーカーである糞便カルプロテクチンを大幅に減少させた(-22.0% vs 8.0%、P=0.03)。
結論:
- ファスティング模倣食(FMD)は、軽度から中等度のクローン病(CD)における臨床的奏効、寛解、および生化学的マーカーの改善において、標準食よりも優れている。
- FMDは、CDのような慢性炎症性疾患の管理における補助療法として可能性を示している。
- 炎症性疾患におけるFMDの長期的な利点とメカニズムをさらに探求するためのさらなる研究が必要である。
関連する概念動画
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
635
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
635
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Metabolic States of the Body: Fasting and Starvation
2.7K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
2.7K
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143


